Ophthalmology Times Newsletter

To view this email as a web page, click here.

Intraoperative surgical methods key to AMD treatment

Targeted subretinal surgery for delivery of a novel biosynthetic retinal pigment epithelial (RPE) monolayer in eyes with advanced dry age-related macular degeneration (AMD) has been shown to be feasible using new intraoperative surgical methods, according to Amir H. Kashani, MD, PhD.

Find out more

Treating dry eye with recombinant human nerve growth factor

Moderate-to-severe dry eye disease is coming under attack from a new direction. Oxervate (Dompé), a first-in-class recombinant human nerve growth factor (rhNGF) that successfully treats neurotrophic keratitis, is being investigated in a phase IIb trial to see how patients with moderate-to-severe dry eye disease fare with this therapy.

Learn more

Gene therapy for LHON: Deciphering phase III data

Phase III studies of a gene therapy for Leber Hereditary Optic Neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data.

Read on

Budding technology could be an OCT analysis game-changer

Weigh risk, benefits of cataract surgery for your patients

Teleglaucoma lets patients be more engaged in care

Safety key for intracamerally injected mydriatic agents in cataract surgery

Understand the expanding role of IPL in dry eye disease

These 3 things are part of a cataract surgeon’s signature

10 effective habits of a cataract surgeon

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.